TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Respiration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: gamma-GCS heavy subunit expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gamma-GCS light subunit expression level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable clinical outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: favorable radiographic outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response to electric pulp test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: declines in the informed subscale of decisional conflict
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Return rate of evaluations
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of students omitting items
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Length of responses to open-ended questions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: hemorrhagic stroke
Endpoint domain: Mortality/survival
Primary endpoint: stroke or SE composite outcome
Endpoint domain: Mortality/survival
Primary endpoint: Pain control (VAS 24 hrs after surgery)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of postoperative ileus
Endpoint domain: Adverse events/effects
Primary endpoint: Height at 40 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Head circumference at 40 weeks of gestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum IGFBP3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PASI50 response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability Index change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Vasodilation to acetylcholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in burden
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement in relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: overall CRC incidence
Endpoint domain: Mortality/survival
Primary endpoint: overall CRC mortality
Endpoint domain: Mortality/survival
Primary endpoint: sexual risk behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of oxidative stress (plasma malondialdehyde)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower inflammatory markers (tumor necrosis factor-alpha)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: increased adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: respiratory events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose to Organs at Risk (OAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Radiation outcomes
Primary endpoint: Homogeneity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retraction duration of the mandibular arch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morbidity and mortality during the first 24 months of life
Endpoint domain: Mortality/survival
Primary endpoint: Mean steady‐state plasma concentrations of 5‐ASA and Ac‐5‐ASA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total urinary excretion of 5‐ASA and Ac‐5‐ASA as a percentage of the given dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in malaria episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Insulin sensitivity (S (I))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pain scores at rest and during mobilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of postoperative sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Parental separation scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in objectively measured symptoms of urgency, incontinence, and frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic Blood Pressure (SBP) Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Blood Pressure (DBP) Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Skin blood flux changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 mental health component scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: global oxygen delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous microvascular flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous tissue oxygen partial pressure (PtO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of calcitriol 3 microg/g ointment in treating psoriasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety profile of calcitriol 3 microg/g ointment
Endpoint domain: Adverse events/effects
Primary endpoint: Detection rates of aggressive prostate cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Extraction force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of hip bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Glucose AUC during exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal LBGI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of samples fully contaminated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Plasma PAI-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improving chronic pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of vertigo episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of subsequent MACE
Endpoint domain: Mortality/survival
Primary endpoint: sustained efficacy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acceptable safety profiles
Endpoint domain: Adverse events/effects
Primary endpoint: high patient retention rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: First implant success rate
Endpoint domain: Adverse events/effects
Primary endpoint: Complications within 24 hours
Endpoint domain: Adverse events/effects
Primary endpoint: Mean LV lead stimulation threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: emotional disturbance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: fluid absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: potassium absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Predictive performance (accuracy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Robustness against data perturbation (relative standard deviations)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrent seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subepineurial ink deposition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of subjects experiencing small bowel mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Postoperative subconjunctival hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: decrease in effective arterial blood volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: EMS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 10-MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AHI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postoperative analgesia requirement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: periwound temperature increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dysrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Normalization of miRNA profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-treatment ovulation rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of miR-451a for diagnosing PCOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiac events (MACE) rates
Endpoint domain: Mortality/survival
Primary endpoint: Psychological anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coagulation activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Oxygen content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset of action of insulin aspart
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in depression levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: pooled prevalence rate of stunting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sexual satisfaction rate of patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sexual satisfaction rate of partners
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative nausea and vomiting (PONV) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in FA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decrease in ADC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean post-treatment CARIFS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CARIFS global VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Local skin oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plethysmography effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GTN plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitrectomy rate in patients with mild-to-moderate VH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recurrence of VH
Endpoint domain: Adverse events/effects
Primary endpoint: Language lateralization index (LI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Five-year progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Frequency of lapses of attention during PVT performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median reaction time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FOSQ total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FTT scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Total score of intestinal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anal resting pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of low anterior resection syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: High Frequency (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: average sensitivity after whitening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Algorithm line failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central retinal thickness measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal volume measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowering of LDLc
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improvement in constructive communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: decrease in conflictual behaviors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: increase in active listening
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: microOR availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: withdrawal symptom suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall HAQ score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical component score (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall PC detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Inter-observer reliability of ultrasound urethral mobility measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gene expression changes related to inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Angle deviation during intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: aerobic fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systemic clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central volume (V1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-load glucose tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ONHBF (Optic Nerve Head Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: ChBF (Choroidal Blood Flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: MFV (Mean Flow Velocity) in the ophthalmic artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Quality of Nursing Working Life (QNWL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Breastfeeding self-efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding exclusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of serious infections
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of tuberculosis (TB)
Endpoint domain: Adverse events/effects
Primary endpoint: Standardised incidence ratio for lymphoma
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in frequency of partial seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prevention of secondarily generalized seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in VISA-A score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in VAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OAG score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: OM repair time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Life scores (FSI, VAS-Fatigue, FACT-Anemia)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean levels of HDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Radiographic assessment in RA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical function component of the Short Form‐12
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Macroscopic thrombus material retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Large thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Combined TIMI grade III flow and myocardial blush grade III
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of early AMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in reflective TNSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAC progression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial desaturation (SpO2 < 90%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on salivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: At least 50% improvement in facial telangiectasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of pain
Endpoint domain: Adverse events/effects
Primary endpoint: risk of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intensity of pain scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increment in intact GLP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of knowledge about health effects from TV programmes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: complete recanalization rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete response (ALT normalization and HBV DNA loss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total withdrawal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet yield per unit of blood volume processed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Processing time for 4000 mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mild donor reactions
Endpoint domain: Adverse events/effects
Primary endpoint: mean yield of lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Collagen‐adenosine diphosphate closure time (CADP‐CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: short-term bleeding rates
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of CIN2+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of HPV screening for CIN3+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV‐1 RNA level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of safety and efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: allergen-induced eosinophilic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Intentional binding task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aberrant bodily experiences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain complaints
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: bacteriological conversion rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients completing treatment
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Markers of inflammation (IL-6, CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes